Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Ex-vivo Antitubercular Activity of PBTZ169 Formulation

NCT03423030 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

32

Enrollment

OTHER

Sponsor class

Conditions

Tuberculosis
Tuberculosis, Pulmonary

Interventions

DRUG: PBTZ169 Formulation
DRUG: Placebo
DRUG: PBTZ169 NCP

Sponsor

Innovative Medicines for Tuberculosis

Collaborators

[object Object]